All In Biotech

Drug Trial Radar · NCT05406440

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, PK and the Effect of MK-8189 on QTc in Participants With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Jul 12, 2022

Primary completion

Feb 24, 2023

Study completion Feb 24, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • ElpipodectDrug

    MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.

  • PlaceboDrug

    MK-8189 dose-matching placebo tablets will be administered orally QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing an Adverse Event (AE)Time frame: Up to approximately 17 days
  2. Number of Participants Who Discontinue From Study Treatment Due to an AETime frame: Up to approximately 3 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC ( Site 0004)

    Garden Grove, California

  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)

    Glendale, California

  • Hassman Research Institute Marlton Site ( Site 0003)

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.